Clinical and Epidemiological Profile of Elderly Patient with Resistant Hypertension

V.A. Skybchyk, S.D. Babliak, Yu.O. Matviienko

Abstract


In this article the authors compare the demographic and clinical parameters in the patients with resistant and controlled hypertension. The results from 5 large foreign studies with similar goals were analyzed. The differences associated with both social and clinical features of these target groups were systematized, including the presence of comorbidities and additional risk factors.


Keywords


resistant hypertension; controlled hypertension; demographic and clinical differences

References


Артеріальна гіпертензія. Оновлена та адаптована клінічна настанова, заснована на доказах (2012 р.) / Робоча група з артеріальної гіпертензії УАК // Артеріальна гіпертензія. — 2012. — № 1(21). — С. 96-152.

Горбась І.М. Програма профілактики і лікування артеріальної гіпертензії в Україні: підсумки виконання / І.М. Горбась // Здоров’я України. Тематичний номер. — 2011. — № 3. — С. 32-34.

ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: ALLHAT // JAMA. — 2002. — Vol. 288. — P. 2981-2997.

Banegas J., Esther Lopez-Garcia E., Dallongeville J. et al. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study // European Heart Journal. — 2011. — Vol. 32. — P. 2143-2152.

Calhoun D.A., Jones D., Textor S. et al. Resistant hypertension: Diagnosis, evaluation and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research // Hypertension. — 2008. — Vol. 51. — P. 1403-1419.

Dahlof B., Devereux R.B., Kjeldsen S.E. et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol // Lancet. — 2002. — Vol. 359. — P. 995-1003.

De la Sierra A., Segura J., Banegas J.R. et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring // Hypertension. — 2011. — Vol. 57. — P. 898-902.

Fagard R.H. Resistant hypertension // Heart. — 2012. — Vol. 98. — P. 254-261.

Muiesan M.L., Pasini G., Salvetti M. Cardia and Vascular structural changes. Prevalence and revalation to ambulatory blood pressure in a middle-aged general population in northern Italy: the Vobarno Study // Hypertensia. — 1996. — Vol. 27. — P. 1046-1052.

Muxfeldt S.E., Nogueiro A.R., Salles G.F., Bloch K.V. Demographic and clinical characteristics of hypertensive patients in the internal medicine outpatient clinic of university hospital in Rio de Janeiro // Sao Paolo Med. J. — 2004. — Vol. 122. — 87-93.

Pepine C.J., Handberg E.M., Cooper-DeHoff R.M. et al. A calcium antagonist vs a noncalcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial // JAMA. — 2003. — Vol. 290. — P. 2805-2816.

Persell S.D. Prevalence of Resistant Hypertension in the US, 2003–2008 // Hypertension. — 2011. — Vol. 57. — P. 1076-1080.

Wolf-Maier K., Cooper R.S., Kramer H. et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada and the United States // Hypertension. — 2004. — Vol. 43. — P. 10-17.




DOI: https://doi.org/10.22141/2224-1485.6.38.2014.82784

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru